Semaglutide is the near-term prize, though the latest print cooled as US generics margin compression lingers; priced richly, the market already expects it to land.
Overall read
4.7/10
Weak & rich
The three reads · this quarter
Semaglutide is the near-term prize, though the latest print cooled as US generics margin compression lingers; priced richly, the market already expects it to land.
Overall read
4.7/10
Weak & rich
The three reads · this quarter
The standing reads · change less often
Moat
Moderate edge
39-year diversified pharma franchise — India-branded brand pull at 50 bps over IPM; Revlimid windfall ending caps STRONG.
Key variables
4 tracked
lead: US New Product Launches (quarterly)Launch cadence has held at 6–10 products per quarter throughout the window, supporting the US revenue base despite Lenalidomide erosion. Ten launches in Q3 FY26 is the strongest single-quarter reading in the tracked period. The pipeline depth of ~280 pending ANDAs provides visibility through at least FY28; the key question is whether complex products (GLP-1, injectables, biosimilars) are within that pipeline or concentrated in lower-margin oral solids.
Walk the talk
Semaglutide global launch and supply resumption is the most significant near-term catalyst, targeting 6-7M pen sales by March 2027 and 12M in FY27, with first-to-market advantage in Canada and multiple other markets.
Latest · newest first
2w ago · Business Update
Change in senior management personnel at the company.
4w ago · Business Update
Company issued a press release with material business update.
4w ago · Business Update
Transcript of earnings call released.
4w ago · Product & Approvals
Dr Reddys receives Thailand approval for first-in-class gonorrhoea drug after US nod.
23 Jul 2026 · Business Update
Announcement under Regulation 30 regarding change in management.
Not enough tracked guidance to grade yet.
Where it sits